The Effect of the Nutraceutical "Hemofix" on the Coagulation System

• Sponsor: Hadassah Medical Organization (Other)
• Overall Status: Withdrawn
• CT.gov ID: NCT01651468
• Collaborator: HEMOFIX (Other), Yocheved Grossman (Other), Idan Grossman (Other)
• Enrollment: 0
• Location: 1
• Arm: 1
• Duration (Months): 87
• Patients Per Site Per Month: 0

Study Details

Study Description

Brief Summary

Hemofix is a herbal formula based on traditional Jewish and far eastern medicine created to assist in wound healing and bleeding arrest. It contains herbs such as Red Clover, Liquorice, Raspberry, Ginger and more. The present study will evaluate the formula on the coagulation system.

Condition or Disease	Intervention/Treatment	Phase
Von Willebrand Disease; Menorrhagia	Dietary Supplement: HEMOFIX	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 0 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Supportive Care
• Official Title: Phase 1 Study of the Nutraceutical "Hemofix" Safety and Effect on the Coagulation System
• Study Start Date: Sep 1, 2016
• Anticipated Primary Completion Date: Jan 1, 2020
• Anticipated Study Completion Date: Dec 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: HEMOFIX 3 grams a day	Dietary Supplement: HEMOFIX; unique complex herbal mixture

Outcome Measures

Primary Outcome Measures

1. bleeding and blood test results [one year]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 75 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Healthy volunteers and volunteers with a mild bleeding disorder

Exclusion Criteria:

• people with thrombophilic and cardiovascular complications,

• people who are treated with anti-coagulants,

• women taking birth control pills

• people with a history hypercoagulability

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hadassah Medical Organization	Jerusalem		Israel

Sponsors and Collaborators

• Hadassah Medical Organization
• HEMOFIX
• Yocheved Grossman
• Idan Grossman

Investigators

• Principal Investigator: David Varon, Prof, HMO

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Hadassah Medical Organization
• ClinicalTrials.gov Identifier: NCT01651468
• Other Study ID Numbers: HEMOFIX- HMO-CTIL
• First Posted: Jul 27, 2012
• Last Update Posted: Nov 28, 2017
• Last Verified: Feb 1, 2017

• Keywords provided by Hadassah Medical Organization: mild bleeding disorder
• Additional relevant MeSH terms: Menorrhagia; Von Willebrand Diseases

Study Results

No Results Posted as of Nov 28, 2017